# Intensive Urate Lowering Therapy of Febuxostat Compared to Allopurinol on Cardiovascular Risk in Patients With Gout

> **NCT02500641** · PHASE4 · COMPLETED · sponsor: **Menarini International Operations Luxembourg SA** · enrollment: 196 (actual)

## Conditions studied

- Gout

## Interventions

- **DRUG:** Febuxostat 80/120mg/day
- **DRUG:** Allopurinol 100 up to 600mg/day
- **DRUG:** Colchicine
- **DRUG:** Naproxen
- **DRUG:** Omeprazole

## Key facts

- **NCT ID:** NCT02500641
- **Lead sponsor:** Menarini International Operations Luxembourg SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08-17
- **Primary completion:** 2017-05-10
- **Final completion:** 2017-05-10
- **Target enrollment:** 196 (ACTUAL)
- **Last updated:** 2019-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02500641

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02500641, "Intensive Urate Lowering Therapy of Febuxostat Compared to Allopurinol on Cardiovascular Risk in Patients With Gout". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02500641. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*